Trial Profile
A Phase1, Double-blind, Randomized, Placebo-control, Single Center, Single Dose Administration, Dose Escalation Study to Investigate the Pharmacokinetics, Safety and Tolerability of SA001 in Healthy Male Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Mar 2022
Price :
$35
*
At a glance
- Drugs Rebamipide mofetil (Primary)
- Indications Dry eyes
- Focus Adverse reactions
- Sponsors Samjin Pharmaceutical Company
- 20 Mar 2022 Status changed from active, no longer recruiting to completed.
- 02 Jun 2016 Planned number of patients changed from 40 to 96.
- 02 Jun 2016 Patients are exposed to SA001 in single as well as multiple doses in Dose escalation manner (doses are not mentioned).